-
The AI tools you use every day — Claude, ChatGPT, Gemini — are, in a meaningful sense, frozen in time. They learned everything they know during a multi-month training run, and then the learning stopped. New research published in 2025 and 2026 is attacking this problem from five different angles simultaneously. Here’s what’s actually working,…
-
SciPy 1.0 was published in February 2020. In the twelve months ending October 2025 it was cited 1,731 times. That is a five-year-old methods paper picking up roughly five new citations per day, with the rate still climbing. Its acceleration over the prior year is +94 per month, the third highest in the entire top-300…
-
Most “trending papers” lists are annual cuts: how many times a paper got cited this year versus last. That misses the shape of the curve. A paper that quietly clocked 200 citations evenly across twelve months looks identical to one that went from 5 per month to 40 per month. The second is actually taking…
-
In 2023 the European Society of Cardiology published its first comprehensive guideline on cardiomyopathies. OpenAlex has already logged more than 2,100 citations to that single document, a pace that puts it among the fastest-accelerating clinical papers of 2024. The guideline itself is not the story. The story is what it quietly codified: a drug class…
-
Steven Pinker’s Enlightenment Now proves that, on a 200-year baseline, almost everything is up and to the right. Peter Thiel’s The End of the Future argues that, since 1973, almost nothing in the physical world is. Both can be true. The trick is to plot each metric on its own longest available baseline and see…
-
Peter Thiel said in 2011 that the future had stalled. Ray Kurzweil said in 2005 that the future was on schedule. Reading both texts now, with a 9.3-million-patent corpus running underneath them, the answer is that they were arguing about different decades — and that the inflection between those decades happened, with disconcerting precision, the…
-
What started as a search for hidden innovation in medical devices turned into something bigger — a vision for how AI-driven R&D will need to coordinate across fields, and the infrastructure that doesn’t exist yet.
-
The two largest US flow-battery patent estates belong to a Japanese cable maker and Lockheed Martin. The pure-play startup that trails them is nearly out of cash.
-
In 2024 a machine settled a value of the busy beaver function no human could ever compute by hand — vindicating Kurzweil’s bet on the limits of computation, and the wall that stops both sides.
-
Kurzweil said your NMDA receptors last five days. They barely last one — and he quietly corrected himself. But the argument the number was carrying only got stronger.
-
A cesium chip-scale atomic clock still costs ,000 and needs a laser. Texas Instruments holds 14 patents on a laser-free replacement that runs on a whiff of stinky gas and 5G-radar circuitry.
-
Kurzweil said biotech would deliver radical life-extending therapies in the 2020s. The first human cell-rejuvenation trial cleared the FDA in January 2026 — but no human life has yet been extended.
-
The microneedle was built in 1998 to push vaccines through skin. The company with the most US microneedle patents now runs it backwards — to read glucose — and just won the first FDA clearance for a needle-free sensor.
-
Kurzweil said molecular motors already existed in biology, so nanomachines had to be buildable. He won the physics and lost the engineering: the machines that got built are folded DNA, not diamond gears.
-
One bankrupt company, View Inc., holds 441 US patents on tint-on-command glass and got more the year it collapsed. The survivors quietly switched the chemistry from oxide-on-glass to printable polymer film.
-
Kurzweil bet nanotechnology would remake spaceflight through a carbon-nanotube space elevator. Cheap orbit arrived anyway — from reusable rockets, the one path the elevator community called a dead end.